Angelo and his care partner were compensated by Bristol Myers Squibb for sharing their stories.
In a clinical study, at 30.9 months follow-up (median*), people treated with ABECMA lived without the disease getting worse or passing away (called progression-free survival) for 3 times longer (13.8 months compared with 4.4 months for those on standard treatments).
*Median is the middle number in a group of numbers arranged from lowest to highest.
ABECMA is a powerful treatment that may help control multiple myeloma
How was ABECMA studied?
Every clinical study includes people with different characteristics. This ABECMA study (KarMMa-3) is the only phase 3 trial that specifically included people who all received 3 different kinds of medicine: an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. These medicines are most commonly used in treating multiple myeloma.
In a clinical study of 386 people with relapsed/refractory multiple myeloma, 254 people received ABECMA and 132 people received standard treatment.† Everyone received at least 2 prior medicines. The median* age of people in the study was 63 years old. The youngest person in the study was 30 years old and the oldest person was 83 years old. Results of the clinical study are based on 30.9 months of median* follow-up.
People included in this study had 2 important characteristics that may be seen in those with relapsed/refractory multiple myeloma (RRMM): 100% of people were triple-class exposed‡ and 95% of people were daratumumab refractory.
†People who were given standard treatment received 1 of the following medication combinations: daratumumab, pomalidomide, dexamethasone (DPd); daratumumab, bortezomib, dexamethasone (DVd); ixazomib, lenalidomide, dexamethasone (IRd); carfilzomib, dexamethasone (Kd); or elotuzumab, pomalidomide, dexamethasone (EPd).
‡Patients who have received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Everyone enrolled in the ABECMA clinical study were monitored for results, including:
- The length of time alive and without the cancer getting worse after treatment, called progression-free survival (PFS)
- The percentage of patients whose cancer shrinks or disappears after treatment, called overall response rate (ORR)
- The disappearance of all signs of cancer in response to treatment,§ called a complete response (CR)
- The length of time cancer responded to treatment without growing or spreading, called duration of response (DOR)
§This does not always mean the multiple myeloma has been cured.
When you discuss treatment options with your doctor, it's important to understand that every study includes different types of people. This can help you and your doctor understand how a treatment might work for you.
Results of the clinical study
People who received a one-time infusion‖ of ABECMA lived 3x longer without multiple myeloma coming back or getting worse compared with standard treatment (13.8 months vs 4.4 months)¶
More people achieved an
OVERALL RESPONSE
with ABECMA than with
standard treatment
More people achieved a
COMPLETE RESPONSE
with ABECMA than with
standard treatment
At a median* follow-up of 15.9 months, people who received ABECMA in the clinical study who had a complete response or better
For patients receiving ABECMA, there was a
than those who received standard treatment regimens
‖Treatment process includes blood collection, CAR T cell creation, administration, and side effect monitoring.
¶Progression-free survival results. Progression-free survival is the amount of time a person was alive and without the cancer getting worse after treatment. People in the clinical study were followed for 30.9 months (median*). Individual results may vary.
#People who were given standard treatment received 1 of the following medication combinations: daratumumab, pomalidomide, dexamethasone (DPd); daratumumab, bortezomib, dexamethasone (DVd); ixazomib, lenalidomide, dexamethasone (IRd); carfilzomib, dexamethasone (Kd); or elotuzumab, pomalidomide, dexamethasone (EPd).
**People who received ABECMA in the clinical study who had a partial response or better responded to ABECMA for 14.8 months.
No matter where you are in your treatment journey, it's a good idea to ask your healthcare team about ABECMA to understand your options. Your doctor will consider many factors when deciding if ABECMA is right for you now—or in the future.
Lloyd was compensated by Bristol Myers Squibb for sharing his story.
